• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚罕见病研究与政策:通向公平护理的征程。

Rare diseases research and policy in Australia: On the journey to equitable care.

机构信息

Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

Genetic Metabolic Disorders Service, Sydney Children's Hospitals' Network, Sydney, New South Wales, Australia.

出版信息

J Paediatr Child Health. 2021 Jun;57(6):778-781. doi: 10.1111/jpc.15507. Epub 2021 Apr 16.

DOI:10.1111/jpc.15507
PMID:33861492
Abstract

Almost exactly 10 years after the publication of 'Call for a national plan for rare diseases' in this journal, the Federal Government launched the National Strategic Action Plan for Rare Diseases (the Action Plan) on the 26th of February 2020, in the lead up to Rare Disease Day on the 29th of February - a rare day for rare diseases. The Action Plan is the culmination of effective advocacy by Rare Voices Australia (RVA) and other stakeholders in the rare disease (RD) sector. RVA is the peak body for Australians living with a RD. The organisation works collaboratively with RD organisations, researchers and clinicians. Since the initial call for a RD plan, a number of health-care initiatives and policy changes have gathered apace including expanded antenatal and newborn screening, the increasing application of next generation sequencing and advances in gene and cell therapeutics. The development of new models of care, diagnostic and treatment pathways, and communities of practice have started to ease the considerable burden and inequitable access to care experienced by RD patients and their families. However, much work remains to be done. The Action Plan outlines the actions to bring about the best possible health and well-being outcomes for Australians living with RD. It is centred around three pillars - awareness and education, care and support, research and data - and will be delivered against the principles of person centredness, equity, and sustainable systems and workforce.

摘要

在本期刊发表“呼吁制定国家罕见病计划”近 10 年后,联邦政府于 2020 年 2 月 26 日在罕见病日(2 月 29 日)前夕推出了《国家罕见病战略行动计划》(行动计划)。该行动计划是罕见病之声澳大利亚(RVA)和其他罕见病(RD)领域利益相关者有效倡导的结果。RVA 是澳大利亚 RD 患者的最高机构。该组织与 RD 组织、研究人员和临床医生合作。自最初呼吁制定 RD 计划以来,许多医疗保健举措和政策变化迅速跟进,包括扩大产前和新生儿筛查、越来越多地应用下一代测序以及基因和细胞治疗的进步。新的护理模式、诊断和治疗途径以及实践社区的发展已经开始缓解 RD 患者及其家人所经历的巨大负担和不公平的护理机会。然而,仍有许多工作要做。该行动计划概述了为澳大利亚 RD 患者带来最佳健康和福祉结果的行动。它围绕三个支柱展开——意识和教育、护理和支持、研究和数据——并将在以人为本、公平和可持续系统和劳动力的原则下实施。

相似文献

1
Rare diseases research and policy in Australia: On the journey to equitable care.澳大利亚罕见病研究与政策:通向公平护理的征程。
J Paediatr Child Health. 2021 Jun;57(6):778-781. doi: 10.1111/jpc.15507. Epub 2021 Apr 16.
2
Rare disease registries: a call to action.罕见病登记处:行动呼吁。
Intern Med J. 2017 Sep;47(9):1075-1079. doi: 10.1111/imj.13528.
3
Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases.利益相关者研讨会的主要成果,该研讨会旨在为制定澳大利亚国家罕见病计划提供信息。
Orphanet J Rare Dis. 2012 Aug 10;7:50. doi: 10.1186/1750-1172-7-50.
4
Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.通过实施精准公共卫生框架,改善罕见病的诊断和护理。
Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4.
5
Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges.加强全球罕见病诊断和治疗的公平可及性:证据、政策和挑战综述。
Int J Environ Res Public Health. 2023 Mar 8;20(6):4732. doi: 10.3390/ijerph20064732.
6
Tackling rare diseases at European level: why do we need a harmonized framework?在欧洲层面应对罕见病:我们为何需要一个统一的框架?
Folia Med (Plovdiv). 2007;49(1-2):59-67.
7
Call for a national plan for rare diseases.呼吁制定国家罕见病计划。
J Paediatr Child Health. 2010 Jan;46(1-2):2-4. doi: 10.1111/j.1440-1754.2009.01608.x. Epub 2009 Nov 23.
8
Lessons from implementing the Australian National Action Plan for Endometriosis.澳大利亚子宫内膜异位症国家行动计划实施的经验教训。
Reprod Fertil. 2022 Jun 30;3(3):C29-C39. doi: 10.1530/RAF-22-0003. eCollection 2022 Jul 1.
9
Rare diseases are a 'common' problem for clinicians.罕见病对临床医生来说是个“常见”问题。
Aust Fam Physician. 2015 Sep;44(9):630-3.
10
The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.首届卡塔尔重症监护会议及其《卡塔尔医学杂志》特刊——一个重要的里程碑。
Qatar Med J. 2019 Nov 7;2019(2):1. doi: 10.5339/qmj.2019.qccc.1. eCollection 2019.

引用本文的文献

1
A coordinated multidisciplinary model of care is needed for child and family centered care in pediatric genetic cancer risk services: a scoping review.儿科遗传癌症风险服务中以儿童和家庭为中心的护理需要一个协调的多学科护理模式:一项范围综述。
Fam Cancer. 2025 Jun 20;24(3):55. doi: 10.1007/s10689-025-00474-8.
2
"You get left behind and lost in a complex world of rare care": equity in access to rare disease care-learnings from the Australian Rare Disease Awareness, Education, Support, and Training (RArEST) project.“你被抛在后面,迷失在一个复杂的罕见病护理世界中”:澳大利亚罕见病认知、教育、支持与培训(RArEST)项目中关于罕见病护理可及性公平性的经验教训。
EBioMedicine. 2025 May;115:105710. doi: 10.1016/j.ebiom.2025.105710. Epub 2025 Apr 15.
3
The role of public health in rare diseases: hemophilia as an example.
公共卫生在罕见病中的作用:以血友病为例。
Front Public Health. 2025 Mar 20;13:1450625. doi: 10.3389/fpubh.2025.1450625. eCollection 2025.
4
Experiences of Family Members and Patients with Spinal Muscular Atrophy Under the Multi-Level Medical Security System in Shaanxi Province, China: A Mixed Study.中国陕西省多层次医疗保障体系下脊髓性肌萎缩症患者及其家庭成员的经历:一项混合研究
Healthcare (Basel). 2025 Jan 13;13(2):140. doi: 10.3390/healthcare13020140.
5
Integrated Care for People Living With Rare Disease: A Scoping Review on Primary Care Models in Organization for Economic Cooperation and Development Countries.罕见病患者的综合照护:经合组织国家初级照护模式的范围综述
J Prim Care Community Health. 2025 Jan-Dec;16:21501319241311567. doi: 10.1177/21501319241311567.
6
Scoping Review of Economic Analyses of Rare Kidney Diseases.罕见肾病经济分析的范围综述
Kidney Int Rep. 2024 Sep 12;9(12):3553-3569. doi: 10.1016/j.ekir.2024.09.004. eCollection 2024 Dec.
7
Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu.中国治疗罕见病的高价孤儿药的预算影响分析:来自人口稠密的特大城市成都的证据。
BMC Health Serv Res. 2024 Sep 27;24(1):1123. doi: 10.1186/s12913-024-11632-6.
8
RNA variant assessment using transactivation and transdifferentiation.使用转激活和转分化评估 RNA 变体。
Am J Hum Genet. 2024 Aug 8;111(8):1673-1699. doi: 10.1016/j.ajhg.2024.06.018. Epub 2024 Jul 30.
9
'High hopes for treatment': Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases.“治疗的高度期望”:澳大利亚利益相关者对罕见神经疾病的先进神经疗法的临床转化的看法。
Health Expect. 2024 Jun;27(3):e14063. doi: 10.1111/hex.14063.
10
The psychosocial impact of childhood dementia on children and their parents: a systematic review.儿童痴呆症对儿童及其父母的心理社会影响:系统评价。
Orphanet J Rare Dis. 2023 Sep 7;18(1):277. doi: 10.1186/s13023-023-02859-3.